REGENXBIO Inc.
RGNX· Nasdaq
RGNXREGENXBIO Inc.
Filed Feb 27, 2024 · 10-K · 58 days after period end · 0000950170-24-021161
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $22.21M | $31.35M | $398.66M | $21.45M |
| Net Income | -$62.89M | -$59.94M | $294.02M | -$46.24M |
| EPS Diluted | — | — |
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
| — |
| -$1.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 27, 2024 · 58 d after period end
